While developing methods for extraction and concentration of various adsorbable blood clotting factors (1-3), we found that an extract made by Al(OH)3 adsorption of citrated plasma contained large amounts of proconvertin and only small quantities of prothrombin, Stuart factor (4), and plasma thromboplastin component (PTC) (5). The present report is concerned with the disappearance rate of proconvertin following the rapid intravenous administration of this extract to nine patients with congenital or acquired hypoproconvertinemia.
(Submitted for publication July 6, 1959 ; accepted November 12, 1959) While developing methods for extraction and concentration of various adsorbable blood clotting factors (1-3), we found that an extract made by Al(OH)3 adsorption of citrated plasma contained large amounts of proconvertin and only small quantities of prothrombin, Stuart factor (4), and plasma thromboplastin component (PTC) (5) . The present report is concerned with the disappearance rate of proconvertin following the rapid intravenous administration of this extract to nine patients with congenital or acquired hypoproconvertinemia.
In their original description of congenital proconvertin 1 deficiency, Alexander, Goldstein, Landwehr and Cook (6) indicated that the corrective effect of normal plasma or serum transfusion was lost within 24 hours. After transfusion of whole blood to an infant with severe congenital hypoproconvertinemia, Hitzig and Zollinger (7) found the proconvertin half-life to be 115 to 135 minutes. The half-life was 57 minutes following injection of 20 ml of an extract having a proconvertin potency 30 times that of normal plasma.
Frick (8) stated that the half-life of proconvertin was 5.5 to 6 hours following plasma transfusion in normal subjects made hypoproconvertinemic by the intravenous administration of Warfarin sodium.2 Didisheim, Loeb, Blatrix and Soulier (9) stated that the half-life of proconvertin was 50 to 55 hours, following intravenous admin-istration of a concentrated proconvertin extract to one patient with cirrhosis of the liver.
All previous investigators have been able to demonstrate exponential disappearance curves with only a single component. We have repeatedly found exponential curves with two components in all experiments except that performed on the normal subject. Both the net rise in proconvertin in the blood and the disappearance rate following injection of the extract were dependent on the degree of deficiency in the recipient.
METHODS
All blood was drawn in uncoated glass syringes, immediately mixed with 1/10 volume of 3.2 per cent sodium citrate in 0.7 per cent NaCl and centrifuged at 2,000 rpm for 20 minutes. The plasma was removed and stored in stoppered glass tubes at -200 C.
Proconvertin. This was measured by a modification of the method of Owren and Aas (10), using plasma from two patients (Bi. C. and Bo. C.) with severe congenital proconvertin deficiency as substrate. These patients had normal prothrombin consumption and thromboplastin generation tests and normal concentrations of Stuart factor. Almost identical results were obtained using partially adsorbed beef plasma as substrate in tests on patients having normal Stuart factor concentrations. The proconvertin time was determined after the addition of 0.1 ml 0.025 M CaCl2 to a mixture of 0.1 ml of substrate plasma, 0.1 ml rabbit brain thromboplastin, and 0.1 ml of the patients' plasma (1/10 dilution in 0.85 per cent NaCl). Duplicate tests were done on each sample and the times averaged. The proconvertin concentration was determined by referring to a standardization curve which was constructed separately for each new lot of reagents. All tests in any given experiment were performed on the same day with the same reagents. The standardization curve was constructed by plotting the proconvertin time against the plasma dilution on loglog paper using 1/10 to 1/200 dilutions of normal plasma. The Prothrombin complex and Stuart factor. Prothrombin complex activity was measured by the method of Quick (11) using dehydrated rabbit brain as the source of tissue thromboplastin. Prothrombin and Stuart factor were measured by the method of Hjort, Rapaport and Owren (12) . Stuart factor was measured by the method of Bachmann, Duckert and Koller (13) , which is similar to the method of Sise, Lavelle and Becker (14) except that optimum concentrations of cephalin and Russell viper venom are determined.
Preparation of extract. Citrated (ACD) blood bank plasma, from 1 to 26 days old, was stored in the frozen state until sufficient quantity had been accumulated for extraction (3 to 4 months).3 The plasma was thawed at 370 C to a final temperature of 250 C and mixed with Al(OH)3 (assayed as 2.4 per cent A1203 in water at neutral pH) in 1/75 of the original plasma volume for 30 minutes. After centrifugation the Al(OH)3 sediment was washed with 0.9 per cent NaCI in 3/4 of the original plasma volume for 30 minutes at 25°C and centrifuged. The washed sediment was eluted with 0.08 M Na2HPO4 solution, adjusted to pH 8.0 in 1/4 of the original plasma volume, stirred for 30 minutes at 250 C and centrifuged. The supernatant was decanted and brought to pH 5.6 in a concentration of 40 per cent ethanol at -5°C, suspended in cold water and freezedried. The dried precipitate was dissolved in 1/100 original plasma volume of Plasmanate,4 sterile filtered and stored in the frozen state or lyophilized. The material was tested in rats and rabbits for toxicity and pyrogenicity before use in human subjects.
RESULTS

Clotting factor content
Three lots of extract prepared from 25 to 100 L pools of plasma were used. The content of clotting factors as compared with normal plasma was: proconvertin, 35 to 88 times; prothrombin plus Stuart factor, 6 to 30 times; Stuart factor, 3.6 to 8.6 times; proaccelerin, antihemophilic factor and thrombin absent; and PTC negligible.
Stability
The lyophilized extracts were stable when tested at 18 months, the reconstituted frozen ex- 3 We are indebted to the Irwin Memorial Blood Bank of the San Francisco Medical Society for its cooperation in collecting these plasmas. 4 at the time he received the extracts, he was also exposed to several cases of infectious hepatitis. None of the other five patients who received the same lot of extract, nor those receiving other lots, developed any late sequelae.
Analysis of disappearance curves.
Disappearance curves having two exponential components were obtained in all experiments except the one in the normal subject. The net rise in proconvertin at T = 0 was obtained by extrapolation of the exponentials. The two exponential components (net rise of proconvertin concentration = Ae-kLt + Be-k2t) were determined graphically by subtraction of the extrapolated final slope (Be k2t) from the initial portion of the curve; Ae-kLt was plotted in this way. The net rise in proconvertin at T = 0 is equal to the sum of the extrapolated exponential component intercepts (A+ B) (15) .
A. Severe congenital hypoproconvertinemia. In Figure 1 are shown the results of a single experiment in each of four patients with severe congenital hypoproconvertinemia (N. C., M. R., Bo. C. no. 3 and Bi. C. no. 1). The results of three experiments done on one of these patients (Bo. C.) are shown in Figure 2 . The similarity of the slopes of the disappearance curves is apparent. In seven experiments done on these four patients, the half-time of the first exponential component of the disappearance curve E. Normal subject before and after Warfarin. One normal subject was studied before and after the oral administration of Warfarin. The disappearance curves following administration of the extract are shown in severe congenital deficiencies (Bi. C., Bo. C. and M. R.) with proconvertin concentrations of 1 to 7 per cent had Quick test values of 9 to 12.5 per cent. One patient (N. C.) showed a greater discrepancy, his Quick value being 36 per cent with a proconvertin concentration of only 4 per cent. In all of these patients following injection of the extract the Quick values remained higher than the proconvertin concentration, particularly during the first hour when differences of 35 to 60 per cent were frequently noted. This increased discrepancy gradually diminished toward the end of the experiments and was always gone by the following day. A comparison of the results of these two tests in N. C. following injection of the extract is shown in Figure 5 .
In the one patient with moderate congenital hypoproconvertinemia there was fairly good agreement between the results of the Quick and proconvertin tests both before and after all three injections of extract. Before injection the proconvertin varied between 26 and 35 per cent and the Quick value between 36 and 38 per cent. Following injection the Quick value was usually slightly greater than the proconvertin concentration but there were variations of as great as + 10 per cent.
In the normal subject receiving Warfarin two different situations were observed immediately following injection of the extract, depending upon the amount given. With In all experiments except that performed on the normal subject, disappearance curves having two exponential components were obtained. Both components of the curve had a faster rate in the more severely deficient patients, regardless of whether the cause of the deficiency was congenital or secondary to liver disease or the administration of Warfarin. It is not possible to determine from our data whether the first exponential represents endothelial adsorption, transfer of proconvertin into an extravascular compartment, a change in vitro in the degree of activation of proconvertin. the influence of a cofactor or inhibitor, or some other mechanism. The second exponential appears to measure metabolic destruction since it proceeds at a steady rate to an infinitely small value. Because the mechanism responsible for the first exponential of the disappearance curve is unknown, it is impossible to state why its rate is faster in the severe deficiencies. However, the data derived from the second exponential appear to indicate that the metabolic destruction rate of proconvertin is more rapid the more severe the deficiency. These results suggest that the reduced proconvertin concentration in these conditions may actually be caused by an increase in its rate of 560 -. I destruction as well as by a decreased rate of production.
The apparent disappearance rate of a substance is influenced by its rate both of production and destruction. We have made the fundamental assumption that all of the patients in this study were in a steady state at the time when our experiments were performed. We found no evidence that the rate of production of proconvertin is controlled by its concentration in the blood since there was no correlation between the total proconvertin concentration achieved and its apparent disappearance rate after injection of extract. If the production rate were controlled by the blood level, one would have expected the normal subject, whose proconvertin concentration was raised to 224 per cent, to have experienced a decrease in production rate and therefore to have shown the fastest apparent disappearance rate of the entire group, whereas, in fact, his was one of the slowest. Conversely, while the same subject was receiving Warfarin, a small dose of extract produced an elevation of his proconvertin concentration to a level of only 59 per cent, yet in this experiment the disappearance rate was faster than in any other experiment in the series. However, it is possible that Warfarin, liver disease, and the congenital deficiency state raise special considerations and that in the normal subject in the steady state the production rate of proconvertin is controlled by its level in the blood.
The site and mechanism of destruction of proconvertin are unknown. It does not seem probable that it is normally consumed in a process of continuous in vivo coagulation. If so, its rate of utilization should depend on the availability of other clotting factors. However, in the Warfarin experiments, prothrombin, Stuart factor, and probably PTC were markedly reduced, yet the disappearance rate of proconvertin was as rapid as in the severe congenital deficiencies in which these factors were present in normal concentrations. Furthermore, proconvertin is not required for the production of blood thromboplastin and is not destroyed in the process of blood clotting.
One hypothesis which might explain some of these results would involve the assumption that a part of the proconvertin in the body exists in an extravascular or endothelial compartment. In the severe deficiencies less proconvertin would be present in this compartment and it might, therefore, accept more proconvertin at a faster rate. Conversely, in the less deficient patients the compartment would be more nearly saturated and might be less capable of accepting additional proconvertin. The half-life of the first component of the disappearance curve would be shorter in the former instance than in the latter. The disappearance curve having a single exponential component in the normal subject might be explained on the assumption that the compartment was completely saturated, or at least had a higher concentration of proconvertin than that in the circulating blood.
The fact that the rates of both components of the disappearance curve show a direct relationship to each other suggests that the mechanism for the initial removal of injected proconvertin from the circulating blood may be the same as that for its ultimate destruction. A mechanism involving a greater degree of cellular or membrane permeability might account for the faster disappearance rate of both components of the curve in the severe deficiency states. An increased perfusion rate could result in more rapid delivery of proconvertin to a specific organ of destruction and also to tissues where it is not destroyed and can be fed back to the circulating blood. In this regard, it is of interest to note that Dicumarol significantly increases the initial transvascular transfer of T-1824-labeled plasma protein in the rabbit (16).
The differences between our results and those reported by Hitzig and Zollinger (7) We have re-evaluated Frick's data and find that when the net increase in proconvertin over the baseline value (rather than total concentration) is plotted on semilog paper, the half-time shown by his data is 145 to 165 minutes rather than 330 to 360 minutes. Furthermore, the test he employed did not specifically measure proconvertin but rather a complex composed of proconvertin and Stuart factor. Since the half-time of Stuart factor appears to be longer than that of proconvertin, it is probable that the disappearance rate of the proconvertin was actually very close to that which we obtained. His failure to observe an initial more rapid component in the disappearance curve could have been due to the relatively long time required for the plasma infusion. Equilibrium could already have been established by the time his first observations were made 10 minutes after completion and 40 minutes after starting the plasma infusion.
In reporting a single experiment in a patient with cirrhosis of the liver, Didisheim and co-workers (9) On all of the above occasions the amount of extract administered was sufficient to raise the patient's proconvertin concentration to or above the normal level. Although this effect was transient, the results suggest that if complete normality of the clotting mechanism can be achieved for even a short time it may be sufficient for normal hemostasis and healing to occur. However, since elevation of the Quick test value was of greater degree and longer duration than that of the proconvertin concentration, the possibility must be entertained that the therapeutic effects may have been due, at least in part, to some other unidentified prothrombin conversion accelerator contained in the extracts.
In all of the known blood clotting factor deficiency states except hypoproconvertinemia there is a defect in the intrinsic production of blood thromboplastin. In Stuart factor deficiency and hypoproaccelerinemia there is an additional failure of the extrinsic clotting mechanism which requires tissue thromboplastin for its proper functioning. It is only in hypoproconvertinemia that the coagulation defect is strictly confined to the extrinsic mechanism. It is therefore possible that the cessation of bleeding following the use of extracts which produce such transient restoration to normality may be uniquely associated with proconvertin deficiency states. Similar trials with large doses of concentrated extracts of other clotting factors in the appropriate deficiency states will be required to clarify this point.
SUMMARY
Extracts containing 35 to 88 times the proconvertin concentration of normal human plasma were produced by aluminum hydroxide adsorption of citrated plasma, elution with phosphate buffer, and precipitation of the protein in the eluate at pH 5.6 with 40 per cent ethanol at -50 C. Following 16 injections of these extracts into nine human subjects, net increases in proconvertin of from 46 to 160 per cent were achieved. In one normal subject a disappearance curve with a single exponential component having a half-time of 230 minutes was found. In two mildly deficient and one moderately deficient congenital hypoproconvertinemic patients disappearance curves with two exponential components were found. The half-time of the first component was 18 to 30 minutes and that of the second was 210 to 240 minutes. In four severely deficient congenital hypoproconvertinemic patients, one patient with severe liver disease, and one normal subject receiving oral Warfarin, disappearance curves with two exponential components were found. The halftime of the first component was 11 to 17 minutes and that of the second 85 to 120 minutes.
The average net increase in proconvertin at T = 0 was 104 per cent of the predicted value in the severely deficient patients and 159 per cent in the normal and mildly and moderately deficient patients.
Intravenous administration of the extract on five occasions to two patients with congenital hypoproconvertinemia resulted in prompt cessation of gingival bleeding, epistaxis and rectal bleeding.
